[Skip to Content]
[Skip to Content Landing]

July 2019 - April 2015

Decade

Year

Issue

July 2019, Vol 5, No. 7, Pages 923-1076

Original Investigation

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(7):953-960. doi:10.1001/jamaoncol.2019.0250

This randomized clinical trial examines whether combined sorafenib and hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin is associated with improved survival of patients with hepatocellular carcinoma and portal vein invasion compared with sorafenib alone, the current standard systemic treatment.

Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With “Good Prognosis” Rectal Cancer Eligible for Primary Surgery: The Phase 2 Nonrandomized QuickSilver Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(7):961-966. doi:10.1001/jamaoncol.2019.0186

This nonrandomized phase 2 clinical trial evaluates the safety and feasibility of using magnetic resonance imaging criteria to select patients with “good prognosis” rectal tumors for primary surgery.

Body Composition and Cardiovascular Events in Patients With Colorectal Cancer: A Population-Based Retrospective Cohort Study

Abstract Full Text
JAMA Oncol. 2019;5(7):967-972. doi:10.1001/jamaoncol.2019.0695

This population-based cohort study assesses 5 measures of body composition to determine which measures are associated with major adverse cardiovascular events in patients with colorectal cancer.

Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality

Abstract Full Text
JAMA Oncol. 2019;5(7):975-983. doi:10.1001/jamaoncol.2019.0826

This multiple-cohort study quantifies the association of black race with long-term survival outcomes after controlling for known prognostic variables and access to care among men with prostate cancer.

Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma

Abstract Full Text
JAMA Oncol. 2019;5(7):985-992. doi:10.1001/jamaoncol.2019.0439

This cohort study investigates whether the prevalence of human papillomavirus (HPV) DNA after completion of primary cancer therapy is associated with recurrence-free survival and overall survival among patients with HPV-positive head and neck squamous cell carcinoma.

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(7):993-998. doi:10.1001/jamaoncol.2019.0684

This phase 2 randomized clinical trial examines whether hydroxychloroquine sulfate improves overall survival at 1 year in combination with gemcitabine hydrochloride and nab-paclitaxel among previously untreated adults with metastatic pancreatic cancer.

Assessment of Subcutaneous vs Intravenous Administration of Anti–PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial

Abstract Full Text
open access
JAMA Oncol. 2019;5(7):999-1007. doi:10.1001/jamaoncol.2019.0836

This phase 1 dose-escalation trial compares the safety, tolerability, and pharmacokinetics of PF-06801591, a monoclonal antibody, administered subcutaneously vs intravenously in patients with advanced or metastatic solid tumors.

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis

Abstract Full Text
JAMA Oncol. 2019;5(7):1008-1019. doi:10.1001/jamaoncol.2019.0393

This systematic review and meta-analysis describes the various adverse events associated with PD-1 and PD-L1 inhibitor drugs reported in clinical trials indexed in PubMed, Web of Science, Embase, and Scopus.

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(7):1020-1027. doi:10.1001/jamaoncol.2019.0892

This single-arm phase 2 clinical trial evaluates the margin-negative resection rate in locally advanced pancreatic cancer after neoadjuvant FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) and losartan therapy and individualized chemoradiotherapy.

Treatment-Related Complications of Systemic Therapy and Radiotherapy

Abstract Full Text
JAMA Oncol. 2019;5(7):1028-1035. doi:10.1001/jamaoncol.2019.0086

This cohort study of 1.5 million ED visits examines rates, costs, and outcomes of emergency department visits by patients with cancer who are undergoing chemotherapy or radiotherapy.

Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment

Abstract Full Text
JAMA Oncol. 2019;5(7):1036-1042. doi:10.1001/jamaoncol.2018.6269

This nonrandomized clinical trial of women with ductal carcinoma in situ examines reasons for conversion to mastectomy after magnetic resonance imaging and adherence to radiotherapy use guided by the 12-gene ductal carcinoma in situ score.

Brief Report

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

Abstract Full Text
open access
JAMA Oncol. 2019;5(7):1043-1047. doi:10.1001/jamaoncol.2019.0402

This cohort study examines the pathophysiologic processes of autoimmune tissue and tumor toxic effects in patients with non–small cell lung cancer.

Research Letter

Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer

Abstract Full Text
JAMA Oncol. 2019;5(7):1060-1062. doi:10.1001/jamaoncol.2019.0869

This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TP53 wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.

Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification

Abstract Full Text
JAMA Oncol. 2019;5(7):1062-1064. doi:10.1001/jamaoncol.2019.0902

In this cohort modeling study, the acute myeloid leukemia composite model is updated using the European LeukemiaNet 2017 classification for cytogenetic and/or molecular risks.

Review

Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(7):1049-1054. doi:10.1001/jamaoncol.2018.6737

This systematic review examines the association of immune checkpoint inhibitor therapy with immune-related adverse effects, antitumor activity, and viral load in patients with HIV infection and advanced-stage cancer.

JAMA Oncology Clinical Challenge

Widespread Thickened, Verrucous, Hyperpigmented Plaques in a Woman With Weight Loss

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(7):1055-1056. doi:10.1001/jamaoncol.2018.7153

A 30-year-old woman presented with a history of thickened, verrucous, hyperpigmented plaques distributed symmetrically over her body. She also had recent weight loss and an enlarged thyroid. What is your diagnosis?

A Common Purpuric Rash With Uncommon Association in a Woman With Pedal Edema

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(7):1057-1058. doi:10.1001/jamaoncol.2019.0174

A 70-year-old woman with pedal edema and a history of smoking presented with multiple well-defined, palpable, purpuralike lesions on the lower extremities that gradually extended to the trunk. What is your diagnosis?

Viewpoint

Shaping the Path for a Global Oncology Academic Career

Abstract Full Text
JAMA Oncol. 2019;5(7):931-932. doi:10.1001/jamaoncol.2019.0555

This Viewpoint distinguishes the role of global oncologists and suggests that institutions should take meaningful steps to facilitate and provide incentives for global health careers.

Reimbursing Patients for Participation in Cancer Clinical Trials

Abstract Full Text
JAMA Oncol. 2019;5(7):932-934. doi:10.1001/jamaoncol.2019.0141

This Viewpoint describes the potential benefits associated with reimbursing patients for participation in cancer clinical trials.

Tumor Mutation Burden—From Hopes to Doubts

Abstract Full Text
JAMA Oncol. 2019;5(7):934-935. doi:10.1001/jamaoncol.2019.0626

This Viewpoint discusses the possibilities and limitations of tumor mutation burden as a biomarker for overall survival in non–small cell lung cancer.

Editorial

Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China

Abstract Full Text
JAMA Oncol. 2019;5(7):938-939. doi:10.1001/jamaoncol.2019.0249

Reducing the Morbidity of Rectal Cancer Treatment

Abstract Full Text
JAMA Oncol. 2019;5(7):940-941. doi:10.1001/jamaoncol.2019.0181

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade

Abstract Full Text
JAMA Oncol. 2019;5(7):942-943. doi:10.1001/jamaoncol.2019.0413
Invited Commentary

Obesity and the Importance of Cardiovascular Disease Surveillance After Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2019;5(7):973-974. doi:10.1001/jamaoncol.2019.0676

Racial Inequality in Prostate Cancer Outcomes—Socioeconomics, Not Biology

Abstract Full Text
JAMA Oncol. 2019;5(7):983-984. doi:10.1001/jamaoncol.2019.0812
JAMA Oncology Patient Page

Next Generation Sequencing—Testing Multiple Genetic Markers at Once

Abstract Full Text
free access
JAMA Oncol. 2019;5(7):1076. doi:10.1001/jamaoncol.2019.0453

This JAMA Patient Page describes next generation sequencing, which allows physicians to test many genes of a cancer simultaneously.

Cancer Care Chronicles

Genetic Testing After a Terminal Diagnosis—Providing Purpose

Abstract Full Text
JAMA Oncol. 2019;5(7):936-937. doi:10.1001/jamaoncol.2019.0846

This essay describes the author’s experience as a genetic counselor with a patient with terminal pancreatic cancer.

Comment & Response

Guidelines for Secondary Solid Cancers Among HSCT Recipients

Abstract Full Text
JAMA Oncol. 2019;5(7):1064. doi:10.1001/jamaoncol.2019.0617

Guidelines for Secondary Solid Cancers Among HSCT Recipients—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(7):1064-1065. doi:10.1001/jamaoncol.2019.0636

Granulocyte Colony-Stimulating Factors in Therapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia

Abstract Full Text
JAMA Oncol. 2019;5(7):1065-1066. doi:10.1001/jamaoncol.2019.0737

Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2019;5(7):1066. doi:10.1001/jamaoncol.2019.1088

Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(7):1066-1067. doi:10.1001/jamaoncol.2019.1100

Accounting for Height in an Analysis of Body Fat and Breast Cancer Risk

Abstract Full Text
JAMA Oncol. 2019;5(7):1067-1068. doi:10.1001/jamaoncol.2019.1091

Accounting for Height in an Analysis of Body Fat and Breast Cancer Risk—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(7):1068. doi:10.1001/jamaoncol.2019.1103

Clinical Application of Volatile Organic Compound–Based Exhaled Breath Tests for Cancer Diagnosis

Abstract Full Text
JAMA Oncol. 2019;5(7):1068-1069. doi:10.1001/jamaoncol.2019.1143

Clinical Application of Volatile Organic Compound–Based Exhaled Breath Tests for Cancer Diagnosis—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(7):1069. doi:10.1001/jamaoncol.2019.1158
Correction

Errors in Figure 3

Abstract Full Text
free access
JAMA Oncol. 2019;5(7):1070. doi:10.1001/jamaoncol.2019.1362

Error in Abstract

Abstract Full Text
free access
JAMA Oncol. 2019;5(7):1070. doi:10.1001/jamaoncol.2019.2137

Error in the Figure

Abstract Full Text
free access
JAMA Oncol. 2019;5(7):1070. doi:10.1001/jamaoncol.2019.2255

Error in the Subtitle and Key Points

Abstract Full Text
free access
JAMA Oncol. 2019;5(7):1070. doi:10.1001/jamaoncol.2019.2595
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2019;5(7):926. doi:10.1001/jamaoncol.2018.4768
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2019;5(7):923. doi:10.1001/jamaoncol.2018.4767
×